|Smart Today=Reporter Kim Se-hyung| Samsung Biologics announced on the 22nd that it has signed a contract for consignment production of pharmaceuticals worth 1.1 trillion won with a European pharmaceutical company on the 19th. The long-term contract is for five years until December 31, 2030. This corresponds to 24.42% of last year's sales.
Meanwhile, Samsung Biologics also announced that it plans to acquire 100% of the shares of Human Genome Sciences Inc., a US pharmaceutical manufacturer, for 413.6 billion won through its local subsidiary in the US.
This acquisition of local production facilities in the US is to respond to long-term local demand. It will be purchased from GSK. The scale is 280 million dollars based on the dollar.
Comment (0)
Write a comment.